Formulation Strategies for Nose-to-Brain Drug Delivery
| dc.contributor.author | Manisha Vohra | |
| dc.contributor.author | Mohammad Amir | |
| dc.contributor.author | Amit Sharma | |
| dc.contributor.author | Sheetu Wadhwa | |
| dc.date.accessioned | 2025-12-19T06:35:43Z | |
| dc.date.available | 2025-12-19T06:35:43Z | |
| dc.date.issued | 2022-05-07 | |
| dc.description.abstract | Background: Neurodegenerative disorders such as Alzheimer’s disease, Parkinson’s disease, Multiple Sclerosis, Dementia, and others are becoming more common globally due to people’s changing lifestyles. Furthermore, the presence of the Blood-Brain barrier and other limitations of oral and other routes of administration makes drug delivery to the brain somewhat tricky.As a result, numerous novel drug delivery systems are being developed for drug administration to the brain. However, nose-to-brain administration is one of the most effective, safe, and non-invasive methods. Purpose: To discuss nose-to-brain deliveryas a novel drug delivery system in the treatment of various brain disorders and to provide information about various formulation strategies designed to deliver the drug to the brain effectively. Methods: A preliminary search was conducted in the PubMed, OVID Medline, Embase, ScienceDirect, Web of Science, and Google Scholar databases using keywords such as “Intranasal delivery, nose-to-brain drug transport, formulations for intranasal delivery.” Results: Various marketed formulations for nose-to-brain drug delivery are listed in this review, like naringenin, donepezil, pentamidine, rivastigmine,efavirenz, desvenlafaxine,lamotrigine, haloperidol,nimodipine, olanzapine, valproic acid, ovalbumin,clonazepam,fentanyl citrate, nifedipine in the form of poloxamer chitosan-based nano-formulation, nano-emulsion, chitosan niosomes, chitosan containing emulsion, solid-lipid nanoparticles,PLGA-chitosan nanoparticles, solution, mucoadhesive microemulsion,nanostructured lipid carriers, cationic liposomes,peptide-attached liposomes, multimellar liposomes with their research findings in treating various brain disorders. Conclusion: This review discusses nose-to-brain drug delivery processes, the pathway for its action, advantages over other delivery routes, barriers to this system, and current formulation strategies for nose-to-brain transport. | |
| dc.identifier.issn | 2321-2217 | |
| dc.identifier.issn | 2321-2225 | |
| dc.identifier.other | https://doi.org/10.15415/jptrm.2022.101008 | |
| dc.identifier.uri | https://demodspace.chitkara.edu.in/handle/123456789/265 | |
| dc.language.iso | en | |
| dc.publisher | Chitkara University Publications | |
| dc.subject | Nose-to-brain delivery | |
| dc.subject | Novel drug delivery | |
| dc.subject | Formulation strategies | |
| dc.subject | Neurological disorders | |
| dc.title | Formulation Strategies for Nose-to-Brain Drug Delivery | |
| dc.type | Article |